Back to News
Mar 4, 2026 8:20 AM

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Moderna Inc. (NASDAQ:MRNA) shares are up during Wednesday’s premarket session following a settlement agreement with Arbutus Biopharma Corporation (NASDAQ:ABUS) and Roivant Inc.’s (NASDAQ:ROIV) Genevant Sciences.

Moderna Settles For $950 Million, Eyes Future Growth

The COVID-19 vaccine maker reached a settlement agreement that resolves all litigation related to its COVID-19 vaccine, Spikevax, and its mRESVIA product.

Moderna will make a lump sum payment of $950 million in the third quarter.

The company may face additional payments of up to $1.3 billion, depending on the outcome of a legal appeal regarding government-contractor immunity.

The company said that if the $1.3 billion payment is realized, it would be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry.

CEO Stéphane Bancel emphasized that resolving this legacy matter allows the company to concentrate on its near-term future.

Moderna expects to end 2026 with $4.5 billion to $5 billion in cash and cash equivalents.

“In 2026, we will return to revenue growth and end the year with a strong balance sheet, ...